Proton Therapy Advantages IMRT Advanced Head and Neck Cancers

July 14, 2014 — A new study by radiation oncologists at Mayo Clinic comparing the world’s literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base compared to intensity modulated radiation therapy (IMRT) has found that proton beam therapy significantly improved disease free survival and tumor control when compared to IMRT. The results appear in the journal Lancet Oncology.

“We undertook a systematic review and meta-analysis to compare the clinical outcomes of patients treated with proton therapy with patients receiving photon IMRT,” says senior author Robert Foote, M.D., a radiation oncologist at Mayo Clinic. “Our findings suggest that the theoretical advantages of proton beam therapy may in fact be real.”

Researchers reviewed studies of nasal cavity and paranasal sinus tumors through extensive database searches. They included studies of patients who had no previous treatment — neither primary radiation therapy nor adjuvant radiation therapy — and patients who had recurrent disease. Researchers collected data on overall survival, disease-free survival, and tumor control, at five years and at the patient’s longest follow-up. They used random-effect models to pool outcomes across studies and compared event rates of combined outcomes for proton therapy and IMRT using an interaction test.

Researchers found disease free survival to be significantly higher at five years for patients receiving proton therapy than for patients receiving IMRT (72% versus 50%). Tumor control did not differ between treatment groups at five years however tumor control was higher for patients receiving proton therapy than for IMRT at the longest follow-up (81% versus 64%).

Co-authors include Samir Patel, M.D., Zhen Wang, Ph.D., William Wong, M.D., Mohammad Hassan Murad, M.D., Courtney Buckey, Ph.D., Khaled Mohammed, M.B., B.Ch, Fares Alahdab, M.D., Mohammed Nabhan, M.D., and Steven Schild, M.D., all of Mayo Clinic.

The study was funded by the Mayo Foundation for Medical Education and Research.

For more information: 150years.mayoclinic.org, www.mayoclinic.org, newsnetwork.mayoclinic.org.


Related Content

News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
Subscribe Now